This report describes the case of a 60-year-old male who developed both hypothyroidism and insulin-dependent diabetes mellitus two months after completing a year-long course of pembrolizumab for stage IIIb BRAF-mutated metastatic melanoma. Here, BRAF is linked to metastatic melanoma.